SYNOPSIS In a patient with generalized prostatic carcinoma and hypofibrinogenaemia heparin infusion on four occasions abolished systemic fibrinolysis as determined by euglobulin clot lysis time, bovine fibrin plate assay, thromboelastography, and immunoelectrophoretic demonstration of fibrinogen split products.
SYNOPSIS In a patient with generalized prostatic carcinoma and hypofibrinogenaemia heparin infusion on four occasions abolished systemic fibrinolysis as determined by euglobulin clot lysis time, bovine fibrin plate assay, thromboelastography, and immunoelectrophoretic demonstration of fibrinogen split products.
The pathogenesis of hypofibrinogenaemia in cases of prostatic carcinoma and the possibility of a direct heparin effect on fibrinolysis are discussed. Despite the lack of histological evidence for intravascular coagulation, the findings are considered additional evidence for the view that fibrinolysis in this syndrome may be secondary to intravascular coagulation.
In acquired hypofibrinogenaemia of malignant disease it is usually difficult to distinguish between the disappearance of fibrinogen by fibrinolysis and consumption of this protein by intravascular coagulation. The presence of thrombocytopenia, which may indicate the disappearance of platelets by a clotting process, is not a valid criterion for the differentiation of the two processes because hypofibrinogenaemia in malignant disease is very often associated with neoplastic bone marrow involvement. On the other hand, circulating fibrinolytic activity in the blood may not necessarily be the primary cause of hypofibrinogenaemia but may constitute the physiological consequence of intravascular coagulation. Anticoagulation is an elegant way for the differentiation since it corrects the hypofibrinogenaemia of intravascular coagulation (Merskey, Johnson, Pert, and Wohl, 1964) . The following case report concerns a patient with metastatic carcinoma of the prostate in whom systemic fibrinolysis was repeatedly abolished by heparin treatment.
MATERIALS AND METHODS
Blood collection and routine laboratory assays for blood coagulation factors were performed according to the methods of Duckert (1958) .
Fibrinogen was determined according to the method of Clauss (1957) and in some blood samples also according to that of Schulz (1955) .
Received for publication 9 August 1966. Thromboelastography was performed according to Hartert's method (1951) , the assay being done on 0 25 ml. of oxalated plasma recalcified with 0-1 ml. of 1/10 M calcium chloride.
For euglobulin lysis time determinations, fresh oxalated plasma was diluted with 15 volumes of distilled water and a pH of 5 2 was obtained by gentle shaking in a CO2 atmosphere for three minutes. The precipitate was separated by centrifugation and redissolved in the original plasma volume of buffer. Of this solution, 0 5ml. was clotted with 0 05 ml. of thrombin (55 u/ml.). The lysis time at 37°C. was recorded.
The fibrin plate assay was performed according to the method of Astrup and Mullertz (1952) .
Plasminogen was determined using the method of Alkjaersig, Fletcher, and Sherry (1959a) , normal values ranging from 0-82 to 1-41 caseinolytic units.
Immunoelectrophoresis was performed with the method of Scheidegger (1955) . Dilutions of the reagents were made with 0 9 % NaCl solution.
Anti-human-fibrinogen antibodies were prepared in rabbits according to Gitlin's method (Gitlin, Landing, and Whipple, 1953) . The antiserum was absorbed with human serum. It gave no precipitation line when tested against various concentrations of normal human serum. Plasma heparin was determined with a thrombin titration method (Brogli, 1965) Figure 1 . Because of the insidious extension of the haematomas 25 blood transfusions were given in all. The bilirubin level increased to a maximum of 14 mg. per 100 ml. on 3 June, with a direct fraction of 2-8 mg. per 100 ml. Despite a second trial of oestrogens in high dosage, starting on 28 May, the patient deteriorated and died on 3 June 1965. Necropsy showed a carcinoma solidum simplex of the prostate with osteoplastic metastases in the bones, a few lung metastases, but no involvement of the liver. Foci of extramedullary blood formation were noted in the spleen and liver. Multiple haemorrhages were present in the subcutaneous tissues, mucosae, and various parenchymal organs. No thrombosis was found. Table II summarizes the data on blood coagulation. Hypofibrinogenaemia was demonstrated by the method of Clauss which measures the protein which is capable of clotting, and by the heat-precipitation method of Schulz. Systemic fibrinolysis was documented by the positive fibrin plate assay, the shortened euglobulin lysis time, and by the progressive decrease of amplitude in the thromboelastogram. The fibrinolytic activity as measured by euglobulin lysis time and the thromboelastogram might have been falsely accentuated by the low plasma fibrinogen level. This objection, however, is invalidated by the unequivocal results with the bovine fibrin plate system and by the demonstration of fibrinogen split products in serum and plasma. The formation of the latter by fibrinolysis in vitro is unlikely since the concentration and electrophoretic mobility appear to be approximately the same in the plasma and in the serum of a given blood sample, the first being frozen immediately after venepuncture, the latter being incubated at 37°C. for six hours. However, this possibility cannot be excluded since no inhibitor of fibrinolysis was added to the blood.
RESULTS AND COMMENT
Heparin treatment was started with a single intra- (Marder, Weiner, Schulman, and Shapiro, 1949; Cosgriff and Leifer, 1952) . Tagnon has demonstrated the presence of fibrinolytic activity in the blood of such patients (Tagnon, Whitmore, and Schulman, 1952; Tagnon, Whitmore, Schulman, and Kravitz, 1953; Tagnon, Schulman, Whitmore, and Leone, 1953b) . His evidence pointed to the presence of fibrinolytic activity also in the primary tumour and in the metastases of such tumours, whence it was thought to be released into the blood. This view has been widely accepted (Zeh and Ott, 1954; Soulier, Larrieu, and Wartelle, 1955; Cottier, Leupold, and Scheitlin, 1955; Crane, Ware, and Hamilton, 1955; Bergen and Schilling, 1958; Marchal, Duhamel, Lerousm Nivet, and Samama, 1959; Miller, Miesel, Jackson, and Collier, 1959; Stefan, Chrobak, Nerad, and Groh, 1959; Anderson and Bilsson, 1961; Bredt, 1962; Stocker and Maier, 1964 ). An alternative hypothesis, that of fibrinolysis secondary to intravascular coagulation, has been advanced.
EVIDENCE FOR A PRIMARY FIBRiNOLYSIS Karhausen
and Tagnon (1955) showed that tissue extracts of benign prostatic hypertrophy were able to digest casein directly in vitro and that the plasminogenrich euglobulin fraction of human plasma was not able to increase this process. Both observations favour Tagnon's concept of a proteolytic enzyme secreted by prostatic tumour tissue and a mechanism of fibrinolysis different from the normally observed activation of plasminogen to plasmin. In keeping with this theory are two published cases of prostatic carcinoma with fibrinolysis which had an increased level of plasminogen (Aboulker et al., 1955) . However, Albrechtsen (1959) later demonstrated that prostatic gland extracts have a strong plasminogen activator activity. The observation of a patient whose fibrinolysis was not influenced by dicoumarol for two months treatment for venous thrombosis has been used as an argument against fibrinolysis secondary to intravascular coagulation (Sigstad and Lamvik, 1963) . Moreover, certain published cases of the syndrome did not have thrombocytopenia (Aboulker et al., 1955; Bergen and Schilling, 1958; Andersson and Nilsson, 1961; Boros, Tarnoky, Vereczkey, and Rak, 1962; Miller et al., 1959; Stocker and Maier, 1964 Frick (1956) , is not explained by bone marrow failure and has led to the postulate of intravascular coagulation as the primary cause of hypofibrinogenaemia. Seale, Jampolis, and Bargen (1951) had observed fibrin thrombi in liver, glomeruli, and endocrine organs of such a patient. Cases have been published presenting with fibrinolysis and simultaneous thrombo-embolic complications (Albrechtsen, 1959; Rapaport and Chapman, 1959; Samama, Marchal, and Klotz, 1965) . Finally, fibrinolysis has not been demonstrable in all the patients with prostatic carcinoma and hypofibrinogenaemia (Seale, Jampolis, and Bargen, 1951; Crane, Ware, and Hamilton, 1955; Swan, Wood, and Daniell, 1957; Rapaport and Chapman, 1959) . The assumption that fibrinolysis is secondary to intravascular coagulation implicates the activation of the physiological mechanism of fibrinolysis, and is favoured by the observation of a very low plasminogen level in our patient as well as in two other published cases. (Phillips, Skrodelis, and Furey, 1959) . Moreover, the administration of seven transfusions after admission in our patient was followed by a marked increase of the fibrinolytic activity and of thehaemorrhagic diathesis. In defibrination syndromes of different origin transfusions or fibrinogen infusions have been shown to increase the haemorrhagic tendency (Albrechtsen, 1959; Stefan et al., 1959; Blix, 1961) , possibly by substituting plasminogen. The well-known beneficial effect of epsilon amino-caproic acid on fibrinolysis in this syndromeappears to constitute another argument for the activation of plasminogen, since the drug primarily inhibits this reaction (Alkjaersig, Fletcher, and Sherry, 1959b) . Moreover, Naeye (1962) reported a case of a patient with disseminated carcinoma of the prostate and afibrinogenaemia who developed widespread intravascular thrombosis while under treatment with epsilon-amino caproic acid, and postulated that the fibrinolysis inhibitor had unmasked an underlying process of intravascular coagulation. The repeated rapid suppression of fibrinolysis by heparin in the present patient favours the assumption of intravascular coagulation with secondary fibrinolysis. That no thrombosis was. found at necropsy may be explained by the removal of fibrin deposits by reactive fibrinolysis.
However, heparin itself may have an antifibrinolytic action. The literature on this subject is highly controversial (Halse, 1947; Astrup, Crookston, and McIntyre, 1950; Schidhauser-Kopp and Eichenberger, 1952; Schultze and Schwick, 1952; Astrup and Alkjaersig, 1952; Paly and Kline, 1954; Sandritter, Bergerhof, and Kroker, 1954; Giacomazzi, 1955; Greig, 1956; Buluk and Januszko, 1957; Hume, 1958; Von Kaulla and McDonald, 1958; Lackner and Merskey, 1960; Blix, 1962; Konttinen, 1962; Berkarda, 1963; Bielawiec and Bilsson, 1964; Lewis, Kerber, and Wilson, 1964; Merskey, Jolmson, Pert, and Whol, 1964; Nilsson, Bielawiec, and Bjorkman, 1964) . Whereas some reports indicate an accelerating effect of heparin on fibrinolysis (Halse, 1947; Schultze and Schwick, 1952; Schmidhauser-Kopp and Eichenberger, 1952; Sandritter, Bergerhof, and Kroker, 1954; Giacomazzi, 1955; Greig, 1956; Buluk and Januszko, 1957; Lackner and Merskey, 1960) , others have found no such effect (Nilsson, Bielawiec, and Bjorkman, 1964 ) and some favour a dose-dependent action (Von Kaulla and McDonald, 1958; Konttinen, 1962) , or even a frank inhibition of fibrinolysis by heparin (Astrup, Crookston, and McIntyre, 1950; Astrup and Alkjaersig, 1952; Paly and Kline, 1954; Blix, 1962; Berkarda, 1963; Holemans et al., 1963; Nilsson et al., 1964; Bielawiec and Nilsson, 1964) . The latter results in vitro even prompted the unsuccessful therapeutic use of heparin three days before death in a patient with prostatic carcinoma and fibrinolysis (Miller et al., 1959) . Holemans and co-workers (1963) described the inhibition of activation of fibrinolysis in vitro by heparin concentrations of more than 100,ug. per ml. of plasma.
These authors have calculated that inhibitions of fibrinolysis in vivo would have to be expected only with plasma concentrations of more than 30 ,[g. per ml., which by far exceed the values observed in our patient. However, Nilsson et al. have pointed out that an inhibition of fibrinolysis activation in vivo should be expected with blood heparin concentrations of 1 to 2 units/ml. They found plasmin itself unaffected by heparin. This would explain our observation that heparin concentrations of more than three times those attained in vivo did not inhibit the fibrinolytic activity of our patient's plasma in vitro.
In view of the prompt abolition by heparin of a considerable systemic fibrinolysis in our patient we assume that the suppression of fibrinolysis by heparin was due to its anticoagulating rather than to a still very controversial direct pharmaceutical effect. The observations would then be additional evidence for the view that in metastatic carcinoma of the prostate the proteolytic state is secondary to intravascular coagulation.
